Package Leaflet: Information for the User
Arvalti 20 mg film-coated tablets EFG
Tadalafil
Read the entire package leaflet carefully before you start taking this medicine, as it contains important information for you.
Contents of the package leaflet:
Arvalti contains the active substance tadalafil, which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Arvalti is used for the treatment of erectile dysfunction. After sexual stimulation, Arvalti acts by helping to relax the blood vessels in your penis, allowing the flow of blood into the penis. The result is an improvement in erectile function. Arvalti will not help you if you do not have erectile dysfunction.
It is important to note that Arvalti is not effective if there is no sexual stimulation.Therefore, you and your partner should stimulate each other in the same way as you would if you were not taking a medicine for erectile dysfunction.
Arvalti 20 mg is used for the treatment of erectile dysfunction in adult men. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. Arvalti has been shown to significantly improve the ability to get a hard erect penis suitable for sexual activity.
Do not takeArvalti if:
Warnings and precautions
Consult your doctor or pharmacist before taking this medicine.
Be aware that sexual activity carries a possible risk to patients with heart problems because it puts extra strain on the heart. If you have a heart problem, tell your doctor.
Before taking the tablets, tell your doctor if you:
It is not known if tadalafil is effective in patients who have:
If you experience a sudden decrease or loss of vision or your vision is distorted, blurred while taking tadalafil, stop taking this medicine and contact your doctor immediately.
A sudden decrease or loss of hearing has been observed in some patients taking tadalafil. Although it is not known if these cases are directly related to tadalafil, if you experience a sudden decrease or loss of hearing, stop taking tadalafil and contact your doctor immediately.
Tadalafil is not intended for use by women.
Children and adolescents
This medicine should not be used in children and adolescents under 18 years.
Using Arvalti with other medicines
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Do not take tadalafil if you are already taking nitrates.
Some medicines may be affected by this medicine or may affect how well tadalafil works. Tell your doctor or pharmacist if you are using:
Taking Arvalti with food and drink
Information about the effect of alcohol is in section 3. Grapefruit juice may affect how well this medicine works and should be taken with caution. Consult your doctor for more information.
Fertility
In dogs treated with tadalafil, a decrease in sperm production was observed. A reduction in sperm count has been observed in some men. It is unlikely that these effects will affect fertility.
Driving and using machines
Some men taking tadalafil during clinical trials experienced dizziness. Check carefully how you react to the tablets before driving or using machines.
Arvalti contains lactose and sodium
If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which is essentially sodium-free.
Follow exactly the instructions of your doctor or pharmacist for taking this medicine. If you are unsure, consult your doctor or pharmacist again.
For the treatment of erectile dysfunction
The recommended doseis one 10 mg tablet before sexual activity. If the effect of this dose is too weak, your doctor may increase the dose to 20 mg. The tablets are for oral use.
You may take a 10 mg tablet at least 30 minutes before sexual activity.
This medicine may be effective for up to 36 hours after taking the tablet.
Do not take this medicine more than once a day. Arvalti 10 mg and 20 mg will be used before planned sexual activity and is not recommended for continuous daily use.
It is important to note that tadalafil is not effective if there is no sexual stimulation. Therefore, you and your partner should stimulate each other in the same way as you would if you were not taking a medicine for erectile dysfunction.
Consuming large amounts of alcohol may temporarily lower your blood pressure. If you have taken or are planning to take tadalafil, avoid excessive alcohol consumption (blood alcohol level of 0.08 % or higher), as it may increase the risk of dizziness when standing up.
Consuming large amounts of alcohol may also affect your ability to get an erection.
Method of administration
The tablets are for oral use only in men. Swallow the tablet whole with a little water. The tablets can be taken with or without food.
If you take more Arvalti than you should
Consult your doctor. You may experience side effects described in section 4.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, telephone 91 562 04 20, stating the medicine and the amount taken.
If you forget to take Arvalti
Take your dose as soon as you remember, but do not take a double dose to make up for forgotten doses. Do not take Arvalti more than once a day.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are usually mild to moderate.
If you experience any of the following side effects, stop taking the medicine and seek medical help immediately:
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from the available data)
Other side effects that have been reported:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Myocardial infarction and stroke have also been reported rarely in men taking tadalafil. Most of these men had pre-existing heart problems.
Rarely, cases of sudden loss of vision in one or both eyes have been reported.
Some additional rare side effects have been reported in men taking tadalafil that were not seen in clinical trials. These include:
Frequency not known(cannot be estimated from the available data)
The most commonly reported side effects in men over 75 years old taking tadalafil were dizziness and diarrhoea. In men over 65 years old taking tadalafil, the most commonly reported side effect was diarrhoea.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly via the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Arvalti 20 mg
Core of the tablet: lactose monohydrate, croscarmellose sodium, hypromellose, laurilsulfate sodium, microcrystalline cellulose, magnesium stearate.
Coating of the tablet: Opadry II yellow 32K12884 contains lactose monohydrate, HPMC 2910/ hypromellose, titanium dioxide (E171), triacetin, talc, and yellow iron oxide (E172).
Appearance and packaging
Arvalti 20 mg is a yellow, capsule-shaped, biconvex film-coated tablet, marked with “20T” on one face and plain on the other.
Diameter: 14.10 ± 0.20 mm
Thickness: 6.10 ± 0.20 mm
Arvalti 10 mg is available in packs of 2, 4, 8, 10, or 12 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Cipla Europe NV
De Keyserlei 58-60, Box-19, 2018
Antwerp,
Belgium
Manufacturer
Cipla Europe NV
De Keyserlei 58-60
Box-19, 2018 Antwerp, Belgium
For further information about this medicine, contact the local representative of the marketing authorisation holder:
Cipla Europe NV, Spanish branch
C/Guzmán el Bueno, 133, Edif. Britannia, 28003 Madrid
Date of last revision of this package leaflet:November 2023
Detailed and up-to-date information on this medicine is available on the website of the Spanish Medicines and Healthcare Products Agency (AEMPS) http://www.aemps.gob.es.